1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Compounding Chemotherapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Compounding Chemotherapy Market, by Offering
8.1.1. Outsourced sterile compounding services
8.1.1.1. Market Revenue and Forecast
8.1.2. In-house compounding systems
8.1.2.1. Market Revenue and Forecast
8.1.3. Closed system transfer devices
8.1.3.1. Market Revenue and Forecast
8.1.4. Sterile compounding consumables
8.1.4.1. Market Revenue and Forecast
8.1.5. Validation and compliance services
8.1.5.1. Market Revenue and Forecast
9.1. Compounding Chemotherapy Market, by Preparation Format
9.1.1. Patient-specific doses
9.1.1.1. Market Revenue and Forecast
9.1.2. Batch-compounded doses
9.1.2.1. Market Revenue and Forecast
9.1.3. Ready-to-administer syringes
9.1.3.1. Market Revenue and Forecast
9.1.4. Ready-to-administer IV bags
9.1.4.1. Market Revenue and Forecast
9.1.5. Clinical trial preparations
9.1.5.1. Market Revenue and Forecast
10.1. Compounding Chemotherapy Market, by Care Setting
10.1.1. Hospital pharmacies
10.1.1.1. Market Revenue and Forecast
10.1.2. Oncology clinics
10.1.2.1. Market Revenue and Forecast
10.1.3. Ambulatory infusion centers
10.1.3.1. Market Revenue and Forecast
10.1.4. Home infusion pharmacies
10.1.4.1. Market Revenue and Forecast
10.1.5. Academic medical centers
10.1.5.1. Market Revenue and Forecast
11.1. Compounding Chemotherapy Market, by Compounding Technology
11.1.1. Biological safety cabinets
11.1.1.1. Market Revenue and Forecast
11.1.2. Compounding aseptic isolators
11.1.2.1. Market Revenue and Forecast
11.1.3. Robotic compounding systems
11.1.3.1. Market Revenue and Forecast
11.1.4. Gravimetric verification systems
11.1.4.1. Market Revenue and Forecast
11.1.5. Environmental monitoring systems
11.1.5.1. Market Revenue and Forecast
11.1.6. Label verification systems
11.1.6.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Offering
12.1.2. Market Revenue and Forecast, by Preparation Format
12.1.3. Market Revenue and Forecast, by Care Setting
12.1.4. Market Revenue and Forecast, by Compounding Technology
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Offering
12.1.5.2. Market Revenue and Forecast, by Preparation Format
12.1.5.3. Market Revenue and Forecast, by Care Setting
12.1.5.4. Market Revenue and Forecast, by Compounding Technology
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Offering
12.1.6.2. Market Revenue and Forecast, by Preparation Format
12.1.6.3. Market Revenue and Forecast, by Care Setting
12.1.6.4. Market Revenue and Forecast, by Compounding Technology
12.2. Europe
12.2.1. Market Revenue and Forecast, by Offering
12.2.2. Market Revenue and Forecast, by Preparation Format
12.2.3. Market Revenue and Forecast, by Care Setting
12.2.4. Market Revenue and Forecast, by Compounding Technology
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Offering
12.2.5.2. Market Revenue and Forecast, by Preparation Format
12.2.5.3. Market Revenue and Forecast, by Care Setting
12.2.5.4. Market Revenue and Forecast, by Compounding Technology
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Offering
12.2.6.2. Market Revenue and Forecast, by Preparation Format
12.2.6.3. Market Revenue and Forecast, by Care Setting
12.2.6.4. Market Revenue and Forecast, by Compounding Technology
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Offering
12.2.7.2. Market Revenue and Forecast, by Preparation Format
12.2.7.3. Market Revenue and Forecast, by Care Setting
12.2.7.4. Market Revenue and Forecast, by Compounding Technology
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Offering
12.2.8.2. Market Revenue and Forecast, by Preparation Format
12.2.8.3. Market Revenue and Forecast, by Care Setting
12.2.8.4. Market Revenue and Forecast, by Compounding Technology
12.3. APAC
12.3.1. Market Revenue and Forecast, by Offering
12.3.2. Market Revenue and Forecast, by Preparation Format
12.3.3. Market Revenue and Forecast, by Care Setting
12.3.4. Market Revenue and Forecast, by Compounding Technology
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Offering
12.3.5.2. Market Revenue and Forecast, by Preparation Format
12.3.5.3. Market Revenue and Forecast, by Care Setting
12.3.5.4. Market Revenue and Forecast, by Compounding Technology
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Offering
12.3.6.2. Market Revenue and Forecast, by Preparation Format
12.3.6.3. Market Revenue and Forecast, by Care Setting
12.3.6.4. Market Revenue and Forecast, by Compounding Technology
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Offering
12.3.7.2. Market Revenue and Forecast, by Preparation Format
12.3.7.3. Market Revenue and Forecast, by Care Setting
12.3.7.4. Market Revenue and Forecast, by Compounding Technology
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Offering
12.3.8.2. Market Revenue and Forecast, by Preparation Format
12.3.8.3. Market Revenue and Forecast, by Care Setting
12.3.8.4. Market Revenue and Forecast, by Compounding Technology
12.4. MEA
12.4.1. Market Revenue and Forecast, by Offering
12.4.2. Market Revenue and Forecast, by Preparation Format
12.4.3. Market Revenue and Forecast, by Care Setting
12.4.4. Market Revenue and Forecast, by Compounding Technology
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Offering
12.4.5.2. Market Revenue and Forecast, by Preparation Format
12.4.5.3. Market Revenue and Forecast, by Care Setting
12.4.5.4. Market Revenue and Forecast, by Compounding Technology
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Offering
12.4.6.2. Market Revenue and Forecast, by Preparation Format
12.4.6.3. Market Revenue and Forecast, by Care Setting
12.4.6.4. Market Revenue and Forecast, by Compounding Technology
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Offering
12.4.7.2. Market Revenue and Forecast, by Preparation Format
12.4.7.3. Market Revenue and Forecast, by Care Setting
12.4.7.4. Market Revenue and Forecast, by Compounding Technology
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Offering
12.4.8.2. Market Revenue and Forecast, by Preparation Format
12.4.8.3. Market Revenue and Forecast, by Care Setting
12.4.8.4. Market Revenue and Forecast, by Compounding Technology
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Offering
12.5.2. Market Revenue and Forecast, by Preparation Format
12.5.3. Market Revenue and Forecast, by Care Setting
12.5.4. Market Revenue and Forecast, by Compounding Technology
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Offering
12.5.5.2. Market Revenue and Forecast, by Preparation Format
12.5.5.3. Market Revenue and Forecast, by Care Setting
12.5.5.4. Market Revenue and Forecast, by Compounding Technology
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Offering
12.5.6.2. Market Revenue and Forecast, by Preparation Format
12.5.6.3. Market Revenue and Forecast, by Care Setting
12.5.6.4. Market Revenue and Forecast, by Compounding Technology
13.1. Baxter International Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. B. Braun Melsungen AG
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Fresenius Kabi AG
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Grifols, S.A.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. ICU Medical, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. PharMEDium (Cencora, formerly AmerisourceBergen)
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Nephron Pharmaceuticals Corporation
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. QuVa Pharma, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Wells Pharma of Houston, LLC
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Fagron NV
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
